Delivery Order SPE2DB20D1100-SPE2DB24FE0Y3
Award Date
9/27/24
Potential Completion Date
9/30/24
Potential Value
$14K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml. The $7,225.77 firm fixed-price contract has a completion date of July 22, 2024. This award is not set aside for any specific business category. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for providing a...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $77,601.82 delivery order contract is for the supply of Pulmozyme 1 mg/mL ampuls, a medication used to treat cystic fibrosis. The contract is a firm fixed-price, non-set-aside award with a performance period ending on April 29, 2025. AmerisourceBergen Drug Corp holds a substantial $999,999,999.00 Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $15,849.83, is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml, a medication used to treat cystic fibrosis. The contract has a period of performance through February 19, 2025 and is structured as a firm fixed-price delivery order. This award is part of Amerisourcebergen's...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,410.99 firm fixed-price delivery order is for the supply of Pulmozyme, a medication used in the treatment of cystic fibrosis. The contract has an ultimate completion date of July 26, 2024 and was awarded on July 25, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,817.78, is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml. This is a firm-fixed-price delivery order contract with an ultimate completion date of August 26, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $6,906.45 contract is for the supply of Pulmozyme, a 1 mg/ml ampul with a 2.5 ml volume. The contract has a firm fixed price and is set to expire on June 14, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
This is a $27,880.43 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Pulmozyme 1 mg/ml ampul 2.5 ml. The contract has an ultimate completion date of September 20, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Pulmozyme, a medication used to treat cystic fibrosis, with a ceiling value of $2,583.60 and a performance period ending on May 12, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a critical...
The U.S. Defense Logistics Agency (DLA) has awarded a delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Pulmozyme 1 mg/mL ampul 2.5 mL. The $2,410.99 firm fixed-price contract has a completion date of March 22, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA for a wide range of pharmaceutical products and medical supplies to support the Department of Defense worldwide. This...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,001.35, is for the delivery of Pulmozyme 1 mg/ml ampuls with a 2.5 ml dosage. The contract has a completion date of February 16, 2024 and is a Firm Fixed Price arrangement. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...